Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

OBJECTIVE: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakanishi, Shotaro, Goya, Masato, Tamaki, Mitsuyoshi, Oshiro, Takuma, Saito, Seiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176613/
https://www.ncbi.nlm.nih.gov/pubmed/34082809
http://dx.doi.org/10.1186/s13104-021-05641-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176613/
https://www.ncbi.nlm.nih.gov/pubmed/34082809
http://dx.doi.org/10.1186/s13104-021-05641-5

Ejemplares similares